J2KBIO Co., Ltd. (KOSDAQ:420570)
South Korea · Delayed Price · Currency is KRW 8,570.00
+120.00 (1.42%)
At close: Apr 24, 2026
J2KBIO Revenue
In the year 2025, J2KBIO had annual revenue of 32.97B KRW, down -0.49%. J2KBIO had revenue of 8.61B in the quarter ending December 31, 2025, with 27.22% growth.
Revenue
32.97B
Revenue Growth
-0.49%
P/S Ratio
1.52
Revenue / Employee
610.49M
Employees
54
Market Cap
50.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.97B | -162.83M | -0.49% |
| Dec 31, 2024 | 33.13B | 4.66B | 16.36% |
| Dec 31, 2023 | 28.47B | 12.44B | 77.60% |
| Dec 31, 2022 | 16.03B | 1.81B | 12.75% |
| Dec 31, 2021 | 14.22B | 360.95M | 2.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NGeneBio | 21.24B |
| Ark Solutions | 16.08B |
| ADBiotech | 12.90B |
| MOA Life Plus | 11.22B |
| Eutilex.Co.,Ltd | 10.29B |
| HLB Pep | 4.96B |
| EyeGene | 3.57B |
| SCM Lifescience | 1.54B |